Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Schimmer

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Leukemia|March 16, 2011
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete responseJ M Brandwein, D W Hedley, S Chow, et al.
Leukemia|December 19, 2008
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and overJ M Brandwein, B F Leber, K Howson-Jan, et al.
Current Oncology (Toronto, Ont.)|August 19, 2016
Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemiaH Sibai, J T Seki, T Q Wang, et al.
Leukemia Research|June 2, 2005
Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patientsJ M Brandwein, V Gupta, R A Wells, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 16, 2017
Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled studyM So, M M Mamdani, A M Morris, et al.
Leukemia|September 24, 2011
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cellsN E Franke, D Niewerth, Y G Assaraf, et al.
Cell Death & Disease|July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosingZ Wang, P Dove, X Wang, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Leukemia|March 16, 2011
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete responseJ M Brandwein, D W Hedley, S Chow, et al.
Leukemia|December 19, 2008
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and overJ M Brandwein, B F Leber, K Howson-Jan, et al.
Current Oncology (Toronto, Ont.)|August 19, 2016
Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemiaH Sibai, J T Seki, T Q Wang, et al.
Leukemia Research|June 2, 2005
Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patientsJ M Brandwein, V Gupta, R A Wells, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 16, 2017
Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled studyM So, M M Mamdani, A M Morris, et al.
Leukemia|September 24, 2011
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cellsN E Franke, D Niewerth, Y G Assaraf, et al.
Cell Death & Disease|July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosingZ Wang, P Dove, X Wang, et al.
Pageof 3